Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07OOI
|
||||
Former ID |
DIB018295
|
||||
Drug Name |
[3H]GBR12935
|
||||
Synonyms |
[3H]-GBR12935
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C28H34N2O
|
||||
InChI |
InChI=1S/C28H34N2O/c1-4-11-25(12-5-1)13-10-18-29-19-21-30(22-20-29)23-24-31-28(26-14-6-2-7-15-26)27-16-8-3-9-17-27/h1-9,11-12,14-17,28H,10,13,18-24H2
|
||||
InChIKey |
RAQPOZGWANIDQT-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Sodium-dependent dopamine transporter | Target Info | Inhibitor | [2] | |
KEGG Pathway | Dopaminergic synapse | ||||
Parkinson's disease | |||||
Cocaine addiction | |||||
Amphetamine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
Parkinson disease | |||||
Dopamine receptor mediated signaling pathway | |||||
Pathway Interaction Database | Alpha-synuclein signaling | ||||
Reactome | Na+/Cl- dependent neurotransmitter transporters | ||||
WikiPathways | Monoamine Transport | ||||
NRF2 pathway | |||||
Dopaminergic Neurogenesis | |||||
Parkinsons Disease Pathway | |||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
Neurotransmitter Clearance In The Synaptic Cleft | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4638). | ||||
REF 2 | Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1994 Jan;45(1):125-35. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.